Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.33 |
| ▸ | BAD | Q92934 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9253261 | 0.79 | OPRM1 (0.42) | OPRD1CES2CES1OPRM1CA1 | |
| SCHEMBL9038594 | 0.78 | HTR2A (0.53) | OPRD1CES2CES1DRD2DRD4 | |
| SCHEMBL9256713 | 0.76 | OPRM1 (0.48) | OPRD1CES2CES1OPRM1CA1 | |
| SCHEMBL2539292 | 0.75 | OPRD1 (0.65) | OPRD1CES2CES1HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL2310717 | 0.73 | OPRD1 (0.63) | OPRD1CES2CES1OPRM1 | |
| Bromide SCHEMBL7444095 | 0.73 | OPRD1 (0.63) | OPRD1CES2CES1HTR2AHTR2C | |
| SCHEMBL20622620 | 0.72 | OPRD1 (0.43) | OPRD1CES2CES1DRD2DRD4 | |
| SCHEMBL9257091 | 0.71 | OPRM1 (0.44) | OPRD1CES2CES1HTR2AHTR2B | |
| SCHEMBL21381803 | 0.70 | OPRD1 (0.44) | OPRD1CES2CES1OPRM1CA1 | |
| SCHEMBL10599177 | 0.69 | OPRD1 (0.58) | OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1154996-B1 | AROYL AMINOACYL PYRROLES FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | ORTHO MCNEIL PHARM INC (US) | 2003-11-05 | — | — | EP | claimed |
| US-6573267-B2 | Central nervous system disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-03 | — | — | US | claimed |
| US-20020019436-A1 | Useful aroyl aminoacyl pyrrole compounds | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-02-14 | — | — | US | claimed |
| WO-2002002521-A2 | AROYL AMINOACYL PYRROLE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| US-20010044452-A1 | Aroyl aminoacyl pyrroles for use in the treatment of neuropathic pain | CARSON JOHN R (US) | 2001-11-22 | — | — | US | claimed |
| EP-1154996-A2 | AROYL AMINOACYL PYRROLES FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Ortho-McNeil Pharmaceutical, Inc. (US) | 2001-11-21 | — | — | EP | claimed |
| US-6191142-B1 | Aroyl aminoacyl pyrroles for use in the treatment of neuropathic pain | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-02-20 | — | — | US | claimed |
| WO-2000048584-A2 | AROYL AMINOACYL PYRROLES FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-08-24 | — | — | WO | claimed |
| US-5532240-A | ANTIPSYCHOTIC AGENTS AND ANTISEROTONIN AGENTS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1996-07-02 | — | — | US | claimed |
| US-5470851-A | Antihistamine, anticoagulants | SANKYO COMPANY, LIMITED (JP) | 1995-11-28 | — | — | US | claimed |
| EP-0463873-A1 | Thiazolidinecarboxylic acid amide derivatives having anti-allergic activity, their preparation and their use | Sankyo Company Limited (JP) | 1992-01-02 | — | — | EP | claimed |
| EP-1351950-B1 | ISOQUINOLINYL AROYL PYRROLE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1154996-B1 | AROYL AMINOACYL PYRROLES FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | ORTHO MCNEIL PHARM INC (US) | 2003-11-05 | — | — | EP | disclosed |
| EP-1351950-A2 | ISOINDOLYL AND ISOQUINOLINYL AROYL PYRROLE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-10-15 | — | — | EP | disclosed |
| US-6573267-B2 | Central nervous system disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-03 | — | — | US | disclosed |
| WO-2000048584-A2 | AROYL AMINOACYL PYRROLES FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-08-24 | — | — | WO | disclosed |
| US-5691330-A | ANTIPSYCHOTIC AGENT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-11-25 | — | — | US | disclosed |
| US-5532240-A | ANTIPSYCHOTIC AGENTS AND ANTISEROTONIN AGENTS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1996-07-02 | — | — | US | disclosed |
| US-5470851-A | Antihistamine, anticoagulants | SANKYO COMPANY, LIMITED (JP) | 1995-11-28 | — | — | US | disclosed |
| EP-0463873-A1 | Thiazolidinecarboxylic acid amide derivatives having anti-allergic activity, their preparation and their use | Sankyo Company Limited (JP) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044452-A1 | Aroyl aminoacyl pyrroles for use in the treatment of neuropathic pain | OPRL1, AADAT, OPRK1 | OPRD1 7/4885CES2 1850/4885CES1 3280/4885 |
| US-20020019436-A1 | Useful aroyl aminoacyl pyrrole compounds | ABAT, GAP43, AADAT | OPRD1 41/4885CES2 1624/4885CES1 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.